Last reviewed · How we verify
Diuretic Increase (DI) — Competitive Intelligence Brief
marketed
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Diuretic Increase (DI) (Diuretic Increase (DI)) — Medtronic BRC. Diuretic Increase (DI) is a device-based therapy from Medtronic that enhances diuretic efficacy, likely through optimized drug delivery or physiological modulation to increase urine output.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diuretic Increase (DI) TARGET | Diuretic Increase (DI) | Medtronic BRC | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diuretic Increase (DI) CI watch — RSS
- Diuretic Increase (DI) CI watch — Atom
- Diuretic Increase (DI) CI watch — JSON
- Diuretic Increase (DI) alone — RSS
Cite this brief
Drug Landscape (2026). Diuretic Increase (DI) — Competitive Intelligence Brief. https://druglandscape.com/ci/diuretic-increase-di. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing